Eli Lilly Escalates Obesity War, Offers Early Access to Next-Gen GLP-1 Retatrutide
The battle for dominance in the lucrative obesity drug market is entering a new and aggressive phase. Eli Lilly has…
Category: Lifestyle
Life-Science Tools Are Being Valued Like Therapeutic Platforms
Biotech’s most revealing deal this week did not center on a drug asset, a phase 3 readout, or a late-stage…
The Obesity Boom Is Becoming a Distribution Crackdown
The latest FDA warning-letter wave shows that the next fight in GLP-1 medicine is shifting from molecule scarcity to control…
No More Excuses: Colon Cancer Screening Just Got a Lot Easier
New American Cancer Society guidelines add at-home stool tests and a blood draw to the screening menu — a timely…
The GLP-1 Supercycle: How the Next Generation of Blockbusters is Reshaping Medicine
From cardiovascular protection to cognitive decline, the race to dominate a projected $300 billion market moves far beyond weight loss…